



The **ONLY** approved
ONCE-DAILY oral *MET* inhibitor¹

Recommended dose is 450 mg once daily with food; please see page 12 to learn more.

IT'S MET TIME

Actor portrayal

For all eligible patients
with *MET*ex14+ mNSCLC¹



National Comprehensive Cancer Network® (NCCN®) Recommendation

Tepotinib is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred systemic therapy option in the first-line/subsequent line* setting for patients with metastatic *MET*ex14+ non-small cell lung cancer (category 2A)^{2†‡§}

*If *MET*ex14+ inhibitors have not previously been given. †Category 2A definition: based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. ‡See the NCCN Guidelines for detailed recommendations, including other preferred options. §The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.²

*MET*ex14+=mesenchymal-epithelial transition exon 14 skipping alterations; mNSCLC=metastatic non-small cell lung cancer.

INDICATION

TEPMETKO® (tepotinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (*MET*) exon 14 skipping alterations.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.


SELECTED IMPORTANT SAFETY INFORMATION

TEPMETKO can cause **interstitial lung disease (ILD)/pneumonitis**, which can be fatal. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Immediately withhold TEPMETKO in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified. ILD/pneumonitis occurred in 2.2% of patients treated with TEPMETKO, with one patient experiencing a Grade 3 or higher event; this event resulted in death.

Please see Important Safety Information throughout and full Prescribing Information.

Early identification helps inform treatment decisions

***MET*ex14+ should be identified at diagnosis as it plays an important role in NSCLC oncogenesis^{3,4}**



Prevalence of Oncogenic Drivers
in Lung Adenocarcinoma⁴⁻⁶

**Based on 2021 estimates,
~6,000 to 8,000 patients may be diagnosed
with NSCLC harboring *MET*ex14+⁷**

3% to 4% of patients may harbor *MET*ex14+⁴

Patients with *MET*ex14+ have been associated with having advanced disease and a poor prognosis.³



National Comprehensive Cancer Network® (NCCN®) recommends²:

- ✧ Clinicians obtain molecular testing results for actionable biomarkers in eligible patients with metastatic NSCLC before administering first-line ICI therapy ± chemotherapy, if clinically feasible[†]
- ✧ Targeted therapies for patients with metastatic NSCLC and specific oncogenic drivers independent of PD-L1 levels
- ✧ For patients who must immediately start therapy but molecular testing is pending, consider holding immunotherapy for one cycle, unless no driver mutations are confirmed present

**MET*ex14+ is a *MET* gene alteration and its estimated frequency in patients with NSCLC varies between studies. *MET*ex14+ is estimated to occur in 2% of squamous cell carcinomas and 8% to 30% of sarcomatoid carcinomas.⁸⁻¹⁰ [†]The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.

ALK=anaplastic lymphoma kinase; BRAF=B-type Raf proto-oncogene; EGFR=epidermal growth factor receptor; ICI=immune checkpoint inhibitor; KRAS=Kirsten rat sarcoma viral oncogene homolog; *MET*=mesenchymal-epithelial transition; *MET* amp=mesenchymal-epithelial transition amplification; *MET*ex14+=mesenchymal-epithelial transition exon 14 skipping alterations; NSCLC=non-small cell lung cancer; PD-L1=programmed death ligand 1; ROS1=c-ros oncogene 1.

Identify *METex14+* at diagnosis

For patients with mNSCLC, *METex14+* identification is critical to help inform treatment decisions^{3,4}

All patients with NSCLC should be considered for biomarker testing regardless of:

METex14+ risk factors



Age⁹

These patients tend to be significantly older than patients with other oncogenic drivers (54 to 65 years of age in ALK, ROS1, EGFR, and KRAS) with an **average age of ~74 years at diagnosis**



Smoking status³

Alterations may occur in both smokers (59%) and never smokers (41%)



Sex¹¹

Equally likely to be either female (49%) or male (51%)



PD-L1 status^{12,13}

~65% may be PD-L1 positive ($\geq 1\%$ expression)


***METex14+* can be detected by an FDA-approved comprehensive biomarker test¹⁴**

The VISION Trial studied 255* patients harboring *MET*ex14+ mNSCLC^{1,14,15}

The largest trial in this patient population

VISION: a single-arm, open-label, multicenter, non-randomized, multicohort trial that studied the efficacy and safety of TEPMETKO® (tepotinib) in adult patients with metastatic NSCLC harboring *MET*ex14+.

The VISION Trial studied a total of 255 patients for safety. Of these patients, 152 were evaluated for efficacy.



Eligibility:	Exclusions:
<ul style="list-style-type: none">⚡ Advanced, metastatic <i>MET</i>ex14+ NSCLC[‡]⚡ EGFR wild-type and ALK-negative status⚡ ≥1 measurable lesion by RECIST v1.1⚡ ECOG PS 0-1	<ul style="list-style-type: none">⚡ Symptomatic CNS metastases⚡ Clinically significant uncontrolled cardiac disease⚡ Prior treatment with any <i>MET</i> or HGF inhibitor

*The number of patients included in the initial analysis that formed the basis for accelerated FDA approval. †In the pre-planned study design, Cohort A reflects the initial analysis that formed the basis for accelerated FDA approval, total of 255 patients also reflected in the Prescribing Information. Cohort C is a prespecified confirmatory cohort for Cohort A, total of 275 patients. Patients were not allowed to enroll in Cohort C until Cohort A was complete. ‡Identification of *MET*ex14+ was prospectively determined using central laboratories employing either a PCR-based or next-generation sequencing-based clinical trial assay using tissue (58%) and/or plasma (65%) samples. An FDA-approved test for detection of *MET*ex14+ in NSCLC for selecting patients for treatment with TEPMETKO is not available. ALK=anaplastic lymphoma kinase; BIRC=Blinded Independent Review Committee; BOR=best overall response; CNS=central nervous system; DCR=disease control rate; DOR=duration of response; ECOG PS=Eastern Cooperative Oncology Group Performance Status; EGFR=epidermal growth factor receptor; HGF=hepatocyte growth factor; mDOR=median duration of response; *MET*=mesenchymal-epithelial transition; *MET*ex14+=mesenchymal-epithelial transition exon 14 skipping alterations; mNSCLC=metastatic non-small cell lung cancer; mOS=median overall survival; mPFS=median progression-free survival; NSCLC=non-small cell lung cancer; ORR=overall response rate; PCR=polymerase chain reaction; QD=once daily; RECIST=Response Evaluation Criteria in Solid Tumors.

SELECTED IMPORTANT SAFETY INFORMATION *continued*

TEPMETKO can cause **hepatotoxicity**, which can be fatal. Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of TEPMETKO, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or total bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue TEPMETKO. Increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST) occurred in 13% of patients treated with TEPMETKO. Grade 3 or 4 increased ALT/AST occurred in

Well-studied in a diverse population

Designed to include patients with clinically relevant diverse profiles^{1,14,16}



Disease characteristics

- 98% had metastatic disease
- 86% had adenocarcinoma histology
- 10% had CNS metastases



Age/ECOG status

- Median age of 73 years (range: 41 to 94 years)
 - 82% were ≥65
- 27% had ECOG PS 0 and 73% had ECOG PS 1



Line of therapy

- 45% first line (n=69)
- 55% previously treated (n=83)*
 - 89% prior platinum-based therapy
 - 46% immune-based therapy



Race and gender

- 71% White
- 25% Asian
- 52% male
- 48% female



Smoking status

- 43% never smokers
- 52% former smokers

The VISION Trial included patients diagnosed by both liquid and tissue biopsies

METex14+ were identified through either PCR or NGS testing^{1†}



- 58% of patients by tissue (RNA-based) testing
- 65% of patients by plasma (ctDNA-based) testing

*Had progressed on up to 2 lines of prior systemic therapies.^{14†}Some patients tested positive using both methodologies.¹⁴
CNS=central nervous system; ctDNA=circulating tumor deoxyribonucleic acid; ECOG PS=Eastern Cooperative Oncology Group Performance Status;
METex14+=mesenchymal-epithelial transition exon 14 skipping alterations; NGS=next-generation sequencing; PCR=polymerase chain reaction.

SELECTED IMPORTANT SAFETY INFORMATION *continued*

4.2% of patients. A fatal adverse reaction of hepatic failure occurred in one patient (0.2%). The median time-to-onset of Grade 3 or higher increased ALT/AST was 30 days (range 1 to 178).

TEPMETKO can cause **embryo-fetal toxicity**. Based on findings in animal studies and its mechanism of action, TEPMETKO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential or males with female partners of reproductive potential to use effective contraception during treatment with TEPMETKO and for one week after the final dose.

Avoid concomitant use of TEPMETKO with dual strong **CYP3A inhibitors** and **P-gp inhibitors** and strong **CYP3A inducers**. Avoid concomitant use of TEPMETKO with certain **P-gp substrates** where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.

Accelerated approval granted

Based on early and positive efficacy data in Cohort A, the FDA granted TEPMETKO® (tepotinib) accelerated approval status^{1,14,16}

TREATMENT NAÏVE (n=69)

The median age of patients in the VISION Trial was 73 years (range: 41 to 94 years).

ORR BY BIRC

43%

(95% CI: 32.0, 56.0)

mDOR BY BIRC

10.8 months

(95% CI: 6.9, NE)

Patients with DOR ≥6 months, 67%
Patients with DOR ≥9 months, 30%

PREVIOUSLY TREATED (n=83)

ORR BY BIRC

43%

(95% CI: 33.0, 55.0)

mDOR BY BIRC

11.1 months

(95% CI: 9.5, 18.5)

Patients with DOR ≥6 months, 75%
Patients with DOR ≥9 months, 50%



National Comprehensive Cancer Network® (NCCN®) Recommendation

Tepotinib is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred systemic therapy option in the first-line/subsequent line* setting for patients with metastatic METex14+ non-small cell lung cancer (category 2A)^{2†‡§}

*If METex14+ inhibitors have not previously been given. †Category 2A definition: based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. ‡See the NCCN Guidelines for detailed recommendations, including other preferred options. §The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.²

BIRC=Blinded Independent Review Committee; DOR=duration of response; mDOR=median duration of response; METex14+=mesenchymal-epithelial transition exon 14 skipping alterations; NE=not evaluable; ORR=overall response rate (confirmed).

SELECTED IMPORTANT SAFETY INFORMATION *continued*

Fatal adverse reactions occurred in one patient (0.4%) due to pneumonitis, one patient (0.4%) due to hepatic failure, and one patient (0.4%) due to dyspnea from fluid overload.


Serious adverse reactions occurred in 45% of patients who received TEPMETKO. Serious adverse reactions in >2% of patients included pleural effusion (7%), pneumonia (5%), edema (3.9%), dyspnea (3.9%), general health deterioration (3.5%), pulmonary embolism (2%), and musculoskeletal pain (2%).

TEPMETKO® (tepotinib) has a manageable safety profile

The safety and tolerability profile of TEPMETKO was studied in 255 patients in the VISION Trial^{1,14,16}

- ⊗ Fatal adverse reactions (ARs) occurred in 1 patient (0.4%) due to pneumonitis, 1 patient (0.4%) due to hepatic failure, and 1 patient (0.4%) due to dyspnea from fluid overload
- ⊗ Serious ARs occurred in 45% of patients who received TEPMETKO. Serious ARs in >2% of patients included pleural effusion (7%), pneumonia (5%), edema (3.9%), dyspnea (3.9%), general health deterioration (3.5%), pulmonary embolism (2%), and musculoskeletal pain (2%)

ARs in ≥10% of patients with NSCLC harboring METex14+¹



Due to an AR in patients who received TEPMETKO¹

- ⊗ **Permanent discontinuation – 20%**
 - The most frequent ARs (>1%) leading to permanent discontinuations of TEPMETKO were edema (5%), pleural effusion (2%), dyspnea (1.6%), general health deterioration (1.6%), and pneumonitis (1.2%)
- ⊗ **Dosage interruptions – 44%**
 - ARs that required dosage interruption in >2% of patients who received TEPMETKO included edema (23%), increased blood creatinine (6%), pleural effusion (4.3%), increased ALT (3.1%), and pneumonia (2.4%)
- ⊗ **Dose reductions – 30%**
 - ARs that required dose reductions in >2% of patients who received TEPMETKO included edema (19%), pleural effusion (2.7%), and increased blood creatinine (2.7%)

Laboratory abnormalities

- ⊗ **Selected laboratory abnormalities (≥20%)** from baseline in patients receiving TEPMETKO in descending order were: decreased albumin (76%), increased creatinine (55%), increased ALP (50%), decreased lymphocytes (48%), increased ALT (44%), increased AST (35%), decreased sodium (31%), decreased hemoglobin (27%), increased potassium (25%), increased GGT (24%), increased amylase (23%), and decreased leukocytes (23%).
- ⊗ **A clinically relevant laboratory abnormality** in <20% of patients who received TEPMETKO was increased lipase in 18% of patients, including 3.7% Grades 3 to 4
- ⊗ **The most common Grade 3-4 laboratory abnormalities (≥2%)** in descending order were: decreased lymphocytes (11%), decreased albumin (9%), decreased sodium (8%), increased GGT (5%), increased amylase (4.6%), increased ALT (4.1%), increased AST (2.5%), and decreased hemoglobin (2%)

*Edema includes eye edema, face edema, generalized edema, localized edema, edema, genital edema, peripheral edema, periorbital edema, peripheral swelling, and scrotal edema. †Fatigue includes asthenia and fatigue. ‡Abdominal pain includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, gastrointestinal pain, and hepatic pain. §Vomiting includes retching and vomiting. ||Musculoskeletal pain includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, non-cardiac chest pain, pain in extremity, and spinal pain. ¶Dyspnea includes dyspnea, dyspnea at rest, and dyspnea exertional. #Cough includes cough, and productive cough. **Pneumonia includes pneumonia, pneumonia aspiration, and pneumonia bacterial.
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyltransferase;
METex14+=mesenchymal-epithelial transition exon 14 skipping alterations; NSCLC=non-small cell lung cancer.

Intracranial disease control

Intracranial responses observed with TEPMETKO® (tepotinib) in patients with brain metastases¹⁷



Systemic efficacy (prespecified analysis)

A predefined subgroup analysis investigated systemic efficacy according to RECIST v1.1 in patients (n=23) with brain metastases at baseline.*

- ◇ **ORR – 47.8%** (95% CI: 26.8, 69.4)
- ◇ **mDOR – 9.5 months** (95% CI: 5.5, NE)
- ◇ **mPFS – 9.5 months** (95% CI: 5.7, 11.2; Events, n=13)



Intracranial activity (retrospective ad hoc analysis)

Intracranial activity was assessed by IRC in a retrospective ad hoc RANO-BM analysis in patients (n=15) with brain metastases at baseline and ≥1 evaluable post-baseline tumor assessment.[†]

- ◇ **Intracranial disease control[‡] observed in 13/15[§] (87%) patients**
- ◇ Of 7 patients with **measurable/target brain lesions** per RANO-BM, **6 patients achieved intracranial disease control** and 1 patient had PD.
 - 71% (5/7) patients achieved PR, including 3 cases of CR in target lesions.
- ◇ Of 8 patients with **non-measurable/non-target brain lesions (NTLs)^{||}**, **7 patients achieved intracranial disease control** and 1 patient had PD.
 - Out of the 7 patients with disease control, 3 patients achieved CR of the enhancing NTL.

Due to the single-arm design of the VISION Trial, no formal statistical comparisons were conducted; data were analyzed in a descriptive manner. For analysis of intracranial activity, brain imaging had no mandatory schedule and, as such, data for this retrospective ad hoc analysis were incomplete, and confirmation of response was not required. Impact of prior radiotherapy on this analysis should be considered. Results are subject to change based on updated analyses. For these reasons, results from these analyses should be interpreted with caution.

*Brain metastases as identified at baseline by IRC or investigator, according to RECIST v1.1. [†]Best overall response per RANO-BM is a composite of radiographic responses, corticosteroid use, and clinical status, giving a more comprehensive overview of the patient compared to RECIST. [‡]Intracranial disease control: Defined as CR/PR/SD or non-CR/non-PD. [§]12 of 15 patients received prior radiotherapy for brain metastases, with a median time between radiotherapy and TEPMETKO of 6.4 weeks (range: 2.6 to 44 weeks). ^{||}For patients with non-measurable lesions only (enhancing and non-enhancing NTLs), non-CR/non-PD was defined as a best objective response of disease control.

CR=complete response; IRC=independent review committee; mDOR=median duration of response; mPFS=median progression-free survival; NE=not evaluable; non-CR/non-PD=non-complete response/non-progressive disease; ORR=overall response rate; PD=progressive disease; PR=partial response; RANO-BM=Response Assessment In Neuro-Oncology Brain Metastases; RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease.

SELECTED IMPORTANT SAFETY INFORMATION *continued*

The most common adverse reactions (≥20%) in patients who received TEPMETKO were edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea.

Clinically relevant adverse reactions in <10% of patients who received TEPMETKO included ILD/pneumonitis, rash, fever, dizziness, pruritus, and headache.

CNS

activity observed with
TEPMETKO® (tepotinib)

CNS=central nervous system.

Actor portrayal



Additional VISION Trial data*

**ADDITIONAL
EXPANDED
ANALYSES***

Data cutoff as
of February 2021

Updated efficacy for Cohorts A[†] + C[‡] (N=275)¹⁵

Due to the single-arm design of the VISION Trial for TEPMETKO® (tepotinib), no formal statistical comparisons were conducted, and data, including PFS and OS, were analyzed in a descriptive manner. For these reasons, results from this analysis should be interpreted with caution.



*Updated data cutoff as of February 2021. Results are based on an interim analysis, which are subject to change on follow-up. [†]The analyses presented here includes all patients enrolled in Cohort A, including 2 patients who were identified as non-responders in the prescribing information, and patients enrolled in Cohort C with 3 months' follow-up. [‡]In the pre-planned study design, Cohort C is a prespecified confirmatory cohort for Cohort A. Patients were not allowed to enroll in Cohort C until Cohort A was complete. [§]ORR according to RECIST v1.1 as evaluated by a BIRC. BIRC=Blinded Independent Review Committee; DCR=disease control rate; mDOR=median duration of response; mOS=median overall survival; mPFS=median progression-free survival; NE=not evaluable; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumors.

SELECTED IMPORTANT SAFETY INFORMATION *continued*

Selected laboratory abnormalities (≥20%) from baseline in patients receiving TEPMETKO in descending order were: decreased albumin (76%), increased creatinine (55%), increased alkaline phosphatase (ALP) (50%), decreased lymphocytes (48%), increased ALT (44%), increased AST (35%), decreased sodium (31%), decreased hemoglobin (27%), increased potassium (25%), increased gamma-glutamyltransferase (GGT) (24%), increased amylase (23%), and decreased leukocytes (23%).

Incidence of treatment-related adverse events

**ADDITIONAL
EXPANDED
ANALYSES***

Data cutoff as
of February 2021

Updated safety data for Cohorts A[†] + C[‡] (N=291)¹⁵

TRAEs, n (%)	Overall (N=291)
Any grade	264 (90.7)
Grade ≥ 3	86 (29.6)
Leading to dose reduction	90 (30.9)
Leading to temporary interruption	114 (39.2)
Leading to permanent discontinuation	41 (14.1)
TRAEs (any grade) occurring in $\geq 10\%$ of all patients	
Peripheral edema	175 (60.1)
Nausea	66 (22.7)
Diarrhea	62 (21.3)
Blood creatinine increase	57 (19.6)
Hypoalbuminemia	55 (18.9)

*Updated data cutoff as of February 2021. Results are based on an interim analysis, which are subject to change on follow-up. [†]The analyses presented here includes all patients enrolled in Cohort A, including 2 patients who were identified as non-responders in the prescribing information, and patients enrolled in Cohort C with 3 months' follow-up. [‡]In the pre-planned study design, Cohort C is a prespecified confirmatory cohort for Cohort A. Patients were not allowed to enroll in Cohort C until Cohort A was complete.

TRAE=treatment-related adverse event.

The ONLY approved once-daily oral *MET* inhibitor¹

Provide your mNSCLC patients with a convenient and flexible dosing regimen that they can stick with



Convenient once-daily dosing

Recommended Starting Dosage: 450 mg
(Two 225 mg tablets)

Advise patients to:

- ⊕ Take their dose at approximately the same time every day until disease progression or unacceptable toxicity
- ⊕ Swallow tablets whole. Do not chew, crush, or split tablets.
- ⊕ Never make up a missed dose within 8 hours of the next scheduled dose. If vomiting occurs after taking a dose, take the next dose at the scheduled time.

Flexible dose adjustment

Dose Reduction for the Management of ARs: 225 mg

- ⊕ Permanently discontinue in patients who are unable to tolerate the 225 mg once-daily dose.
- ⊕ Management of some ARs may require temporary interruption or permanent discontinuation. See the full Prescribing Information for recommended dose modifications of TEPMETKO® (tepotinib).

**One Dose.
Once a Day.**

PATIENT SELECTION

Select patients for treatment with TEPMETKO based on the presence of *MET*ex14+ in plasma or tumor specimens. Testing for the presence of *MET*ex14+ in plasma specimens is recommended only in patients for whom a tumor biopsy cannot be obtained. If an alteration is not detected in a plasma specimen, reevaluate the feasibility of biopsy for tumor tissue testing. An FDA-approved test for detection of *MET*ex14+ in NSCLC for selecting patients for treatment with TEPMETKO is not available.

AR=adverse reaction; *MET*=mesenchymal-epithelial transition; *MET*ex14+=mesenchymal-epithelial transition exon 14 skipping alterations; mNSCLC=metastatic non-small cell lung cancer.

SELECTED IMPORTANT SAFETY INFORMATION *continued*

The most common Grade 3-4 laboratory abnormalities (≥2%) in descending order were: decreased lymphocytes (11%), decreased albumin (9%), decreased sodium (8%), increased GGT (5%), increased amylase (4.6%), increased ALT (4.1%), increased AST (2.5%), and decreased hemoglobin (2%).

A clinically relevant laboratory abnormality in <20% of patients who received TEPMETKO was increased lipase in 18% of patients, including 3.7% Grades 3 to 4.

Help eligible patients gain appropriate access



The EMD Serono Oncology Navigation Center (ONC) is a patient access and reimbursement support program available to help eligible patients gain appropriate access to TEPMETKO® (tepotinib) in the United States*



Reimbursement
support



Bridge program for
new patients with
insurance delays



Co-pay assistance
for privately insured
patients



Patient assistance
program/free drug
program for
eligible patients

The ONC co-pay assistance program is entirely for the benefit of the enrolled patient on TEPMETKO. Full terms and conditions apply.

ONC is available to answer any questions.

OncNavigationCenter.com

Phone: 1-844-662-3631 (844-ONC-EMD1)

Fax: 844-501-0062

Monday-Friday: 8:00 AM-8:00 PM Eastern Time

*Additional program rules and restrictions or conditions may apply. Enrollment Forms and complete program information are available through OncNavigationCenter.com.

Warnings and precautions¹

The safety profile of TEPMETKO® (tepotinib) reflects **exposure to TEPMETKO in 448 patients with various solid tumors**. These patients were enrolled in 5 open-label, single-arm studies, in which they received TEPMETKO as a single agent at a dose of 450 mg once daily. **This included 255 patients with METex14+ mNSCLC, who received TEPMETKO in the VISION Trial.**

Interstitial lung disease (ILD)/pneumonitis

ILD/pneumonitis, which can be fatal, occurred in 2.2% of patients treated with TEPMETKO, with 1 patient experiencing a Grade 3 or higher event that resulted in death. Four patients (0.9%) discontinued TEPMETKO due to ILD/pneumonitis.

Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Immediately withhold TEPMETKO in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified.

Hepatotoxicity

Hepatotoxicity occurred in patients treated with TEPMETKO. Increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST) occurred in 13% of patients treated with TEPMETKO. Grade 3 or 4 increased ALT/AST occurred in 4.2% of patients. A fatal adverse reaction of hepatic failure occurred in 1 patient (0.2%). Three patients (0.7%) discontinued TEPMETKO due to increased ALT/AST. The median time-to-onset of Grade 3 or higher increased ALT/AST was 30 days (range: 1 to 178 days).

Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of TEPMETKO, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue TEPMETKO.

Embryo-fetal toxicity

Based on the mechanism of action and findings in animals, TEPMETKO can cause fetal harm when administered to pregnant women. Oral administration of TEPMETKO during organogenesis in pregnant rabbits resulted in malformations (teratogenicity) and anomalies starting at exposures less than the human exposure based on area under the curve (AUC) at the 450 mg daily clinical dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential or males with female partners of reproductive potential to use effective contraception during treatment with TEPMETKO and for 1 week following the final dose.

METex14+=mesenchymal-epithelial transition exon 14 skipping alterations; mNSCLC=metastatic non-small cell lung cancer.



Actor portrayal

Important Safety Information and Indication¹

IMPORTANT SAFETY INFORMATION

TEPMETKO® (tepotinib) can cause **interstitial lung disease (ILD)/pneumonitis**, which can be fatal. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Immediately withhold TEPMETKO in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified. ILD/pneumonitis occurred in 2.2% of patients treated with TEPMETKO, with one patient experiencing a Grade 3 or higher event; this event resulted in death.

TEPMETKO can cause **hepatotoxicity**, which can be fatal. Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of TEPMETKO, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or total bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue TEPMETKO. Increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST) occurred in 13% of patients treated with TEPMETKO. Grade 3 or 4 increased ALT/AST occurred in 4.2% of patients. A fatal adverse reaction of hepatic failure occurred in one patient (0.2%). The median time-to-onset of Grade 3 or higher increased ALT/AST was 30 days (range 1 to 178).

TEPMETKO can cause **embryo-fetal toxicity**. Based on findings in animal studies and its mechanism of action, TEPMETKO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential or males with female partners of reproductive potential to use effective contraception during treatment with TEPMETKO and for one week after the final dose.

Avoid concomitant use of TEPMETKO with dual strong **CYP3A inhibitors** and **P-gp inhibitors** and strong **CYP3A inducers**. Avoid concomitant use of TEPMETKO with certain **P-gp substrates** where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.

Fatal adverse reactions occurred in one patient (0.4%) due to pneumonitis, one patient (0.4%) due to hepatic failure, and one patient (0.4%) due to dyspnea from fluid overload.

Serious adverse reactions occurred in 45% of patients who received TEPMETKO. Serious adverse reactions in >2% of patients included pleural effusion (7%), pneumonia (5%), edema (3.9%), dyspnea (3.9%), general health deterioration (3.5%), pulmonary embolism (2%), and musculoskeletal pain (2%).

The most common adverse reactions (≥20%) in patients who received TEPMETKO were edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea.

Clinically relevant adverse reactions in <10% of patients who received TEPMETKO included ILD/pneumonitis, rash, fever, dizziness, pruritus, and headache.

Selected laboratory abnormalities (≥20%) from baseline in patients receiving TEPMETKO in descending order were: decreased albumin (76%), increased creatinine (55%), increased alkaline phosphatase (ALP) (50%), decreased lymphocytes (48%), increased ALT (44%), increased AST (35%), decreased sodium (31%), decreased hemoglobin (27%), increased potassium (25%), increased gamma-glutamyltransferase (GGT) (24%), increased amylase (23%), and decreased leukocytes (23%).

The most common Grade 3-4 laboratory abnormalities (≥2%) in descending order were: decreased lymphocytes (11%), decreased albumin (9%), decreased sodium (8%), increased GGT (5%), increased amylase (4.6%), increased ALT (4.1%), increased AST (2.5%), and decreased hemoglobin (2%).

A **clinically relevant laboratory abnormality** in <20% of patients who received TEPMETKO was increased lipase in 18% of patients, including 3.7% Grades 3 to 4.

INDICATION

TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (*MET*) exon 14 skipping alterations.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

See full [Prescribing Information](#).

References

1. TEPMETKO® (tepotinib) [prescribing information]. EMD Serono, Inc., Rockland, MA; 2021.
2. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 5, 2022. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.
3. Awad MM, Leonardi GC, Kravets S, et al. Impact of *MET* inhibitors on survival among patients with non-small cell lung cancer harboring *MET* exon 14 mutations: a retrospective analysis. *Lung Cancer*. 2019;133:96-102. doi:10.1016/j.lungcan.2019.05.011
4. Salgia R. *MET* in lung cancer: biomarker selection based on scientific rationale. *Mol Cancer Ther*. 2017;16(4):555-565. doi:10.1158/1535-7163.MCT-16-0472
5. Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. *Lancet*. 2016;387(10026):1354-1355. doi:10.1016/S0140-6736(15)01125-3
6. Drilon A, Cappuzzo F, Ou SHI, Camidge DR. Targeting *MET* in lung cancer: will expectations finally be *MET*? *J Thorac Oncol*. 2017;12(1):15-26. doi:10.1016/j.jtho.2016.10.014
7. American Cancer Society. About lung cancer. Accessed May 5, 2022. <https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html>
8. Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring *MET* exon 14 skipping alterations. *J Thorac Oncol*. 2016;11(9):1493-1502. doi:10.1016/j.jtho.2016.06.004
9. Tong JH, Yeung SF, Chan AWH, et al. *MET* amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. *Clin Cancer Res*. 2016;22(12):3048-3056. doi:10.1158/1078-0432.CCR-15-2061
10. Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable *MET* gene mutations. *J Clin Oncol*. 2015;34:794-802.
11. Cheng T, Gu Z, Song D, et al. Genomic and clinical characteristics of *MET* exon 14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. *J Cancer*. 2021;12(3):644-651. doi: 10.7150/jca.4939
12. Pruis MA, et al. Highly accurate DNA-based detection and treatment results of *MET* exon 14 skipping mutations in lung cancer. *Lung Cancer*. 2020;140:46-54. doi: 10.1016/j.lungcan.2019.11.010
13. Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with *MET* exon 14 altered lung cancers. *Ann Oncol*. 2018;29(10):2085-2091. doi:10.1093/annonc/mdy334
14. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with *MET* exon 14 skipping mutations. *N Engl J Med*. 2020;383:931-943. doi:10.1056/NEJMoa2004407
15. Garassino MC, Felip E, Sakai H, et al. Tepotinib in patients with *MET* exon 14 skipping non-small cell lung cancer as identified by liquid or tissue biopsy: Interim analysis of the VISION study (NCT02864992) Cohorts A and C. Presented at: Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2022.
16. Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with *MET* exon 14 skipping mutations [supplementary appendix]. *N Engl J Med*. 2020;383:931-943. doi:10.1056/NEJMoa2004407
17. Patel JD, Le X, Veillon R, et al. Intracranial activity of tepotinib in patients with *MET* exon 14 skipping NSCLC enrolled in VISION. Presented at: American Society of Clinical Oncology Annual Meeting, 2021. Abstract 9084.



IT'S MET TIME

Actor portrayal

For all eligible patients with *MET*ex14+ mNSCLC,

CONSIDER TEPMETKO

The only once-daily oral *MET* inhibitor

Recommended dose is 450 mg once daily with food; please see page 12 to learn more.

Dosing flexibility

The **ONLY** approved once-daily oral *MET* inhibitor for all eligible patients with *MET*ex14+ mNSCLC¹



Treat with confidence

Studied in VISION, the **LARGEST** trial in patients with *MET*ex14+ mNSCLC and demonstrated robust and lasting efficacy results with a manageable safety profile¹

–See page 4 for full trial design

CNS activity

Improved intracranial response in patients with brain metastases¹⁷

CNS=central nervous system; *MET*=mesenchymal-epithelial transition; *MET*ex14+=mesenchymal-epithelial transition exon 14 skipping alterations; mNSCLC=metastatic non-small cell lung cancer.

INDICATION

TEPMETKO® (tepotinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (*MET*) exon 14 skipping alterations.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

SELECTED IMPORTANT SAFETY INFORMATION

TEPMETKO can cause **interstitial lung disease (ILD)/pneumonitis**, which can be fatal. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever). Immediately withhold TEPMETKO in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified. ILD/pneumonitis occurred in 2.2% of patients treated with TEPMETKO, with one patient experiencing a Grade 3 or higher event; this event resulted in death.

TEPMETKO can cause **hepatotoxicity**, which can be fatal. Monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of TEPMETKO, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or total bilirubin. Based on the severity of the adverse reaction, withhold, dose reduce, or permanently discontinue TEPMETKO. Increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST) occurred in 13% of patients treated with TEPMETKO. Grade 3 or 4 increased ALT/AST occurred in 4.2% of patients. A fatal adverse reaction of hepatic failure occurred in one patient (0.2%). The median time-to-onset of Grade 3 or higher increased ALT/AST was 30 days (range 1 to 178).

Please see Important Safety Information throughout and full Prescribing Information.